Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70180 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Ian W McKeague und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: Mitochondrial Diseases, Accelerometry, Thymidine Kinase, Outcome Assessment, Health Care. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Objective
Therapeutic development for mitochondrial diseases, rare genetic disorders with pathogenic defects of oxidative phosphorylation, is hindered by unsatisfactory outcome measures. To address this problem, we provide the first clinical application of a novel, bias‐adjusted outcome measure of acceleration across a range of subjects' activities to assess nucleoside therapy for thymidine kinase 2 deficiency, an ultra‐rare autosomal recessive mitochondrial disease.
Methods
Data were collected from treated patients in an ongoing phase 2 clinical trial who served as their own controls. If there is a treatment effect, time‐in‐activity curves for these patients will increase over successive clinic visits. We used a combination of functional data analysis and longitudinal mixed‐effects linear regression, adjusted for age and gender, to test for the effect of treatment length on time‐in‐activity.
Results
For 14 patients with at least two assessments 6 months apart, we found a significant overall improvement of time‐in‐activity due to treatment. Improvement was especially significant at two individual activity levels within the range (0.14 and 2 g). In longitudinal analyses, using data on time‐in‐activity at these two levels for all clinic visits of 19 subjects, the effect of treatment length on time‐in‐activity was highly significant at both 0.14 g (0.04, CI 0.01–0.08, p = 0.023) and 2 g (0.01, 0.00–0.02, p = 0.013).
Interpretation
This small‐N exploratory analysis using a new accelerometer‐based activity measure featuring powerful data reduction and adjustment for circadian rhythms and other biases finds that nucleoside therapy may increase activity levels in thymidine kinase 2 deficiency patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics, Columbia University, New York, New York, USA.
- Department of Neurology, Columbia University, New York, New York, USA.
- Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore.
ORCID-Profile: Kristin Engelstad, Ziwei Zhao, Michio Hirano
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
McKeague, I. W., Engelstad, K., Ge, Y., Tucker, A., Li, S., Uddin, J., Zhao, Z., Thompson, J. L. P., & Hirano, M. (2025). Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70180
Vancouver
McKeague IW, Engelstad K, Ge Y, Tucker A, Li S, Uddin J, et al. Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70180
BibTeX
@article{McKeague2025,
author = {McKeague, Ian W and Engelstad, Kristin and Ge, Yue and Tucker, Amber and Li, Shufang and Uddin, Jasim and Zhao, Ziwei and Thompson, John L P and Hirano, Michio},
title = {Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70180}
}
EUVIMED